Lexeo announces positive interim data for LX2020 in PKP2 cardiomyopathy
Lexeo Therapeutics reported significant reductions in arrhythmia burden in a Phase I/II trial of LX2020, and the FDA has expressed openness to a specific surrogate endpoint for potential accelerated approval, bolstered by a strong cash balance.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed